secwatch / observer

8-K filed September 3, 2025, 7:59 PM ET ticker CYTK CIK 0001061983

other material confidence high sentiment positive materiality 0.75

Cytokinetics presents new aficamten data at ESC 2025; shows improvement vs metoprolol

CYTOKINETICS INC

MAPLE-HCM: aficamten superior to metoprolol on diastolic function, SAM, and LVOT obstruction (p<0.001); reduced max wall thickness (-1.01mm, p=0.015).
Atrial fibrillation annual incidence with aficamten was 1.5%, consistent with predicted HCM-AF and CHARGE-AF rates; minimal clinical impact.
Integrated safety of 463 patients (~700 patient-years) shows similar AE profile to placebo; low LVEF<50% incidence, no permanent discontinuations.
Longer-term FOREST-HCM: 69% and 93% of patients improved NYHA class at Week 12 and 96; KCCQ-CSS +15 and +16.
FDA NDA under review with PDUFA target action date of December 26, 2025.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-112570
form_type: 8-K
ticker: CYTK
cik: 0001061983
company_name: CYTOKINETICS INC
filed_at: 2025-09-03T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.229134+00:00
generated_at: 2026-05-17T08:26:25.201871+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-112570
json_url: https://secwatch.observer/filing/0000950170-25-112570.json
markdown_url: https://secwatch.observer/filing/0000950170-25-112570.md
text_url: https://secwatch.observer/filing/0000950170-25-112570.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017025112570/0000950170-25-112570-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017025112570/cytk-20250831.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

PECE

Peace Acquisition Corp closes IPO of 6M units at $10.00/unit, raising $60M

Peace Acquisition Corp. June 1, 2026, 5:16 PM ET other_material Items 3.02, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MVIS

MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026

MICROVISION, INC. June 1, 2026, 5:02 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VDTA

Vertical Data launches Vertical Edge, a direct-ownership edge data center platform

Vertical Data Inc. June 1, 2026, 4:47 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0000950170-25-112570

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.